Anavex Life Sciences Corp (AVXL)

[Hosai]

It would be absurd and wrong to deprive patients of trying the drug for that long. Just to remind of the EMA conditional approval guidelines:

the benefit-risk balance of the medicine is positive;
it is likely that the applicant will be able to provide comprehensive data post-authorisation;
the medicine fulfils an unmet medical need;
the benefit of the medicine's immediate availability to patients is greater than the risk inherent in the fact that additional data are still required.

https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/conditional-marketing-authorisation